Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Previously Treated Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
NCT03940976Phase 2Unknown
- Sponsor
- Peking University
- Start
- Apr 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University. Status: unknown.
02
Drugs
afatinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03940976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03940976.